BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19362980)

  • 21. Primary systemic amyloidosis with delayed progression to multiple myeloma.
    Rajkumar SV; Gertz MA; Kyle RA
    Cancer; 1998 Apr; 82(8):1501-5. PubMed ID: 9554527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].
    Thierry A; Bridoux F; Goodman H; Belmouaz S; Abou Ayache R; Desport E; Jaccard A; Touchard G
    Nephrologie; 2004; 25(4):111-8. PubMed ID: 15291138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
    Bergesio F; Ciciani AM; Manganaro M; Palladini G; Santostefano M; Brugnano R; Di Palma AM; Gallo M; Rosati A; Tosi PL; Salvadori M;
    Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.
    Palladini G; Foli A; Russo P; Milani P; Obici L; Lavatelli F; Merlini G
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):143-5. PubMed ID: 21454217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosis.
    Meier-Ewert HK; Sanchorawala V; Berk J; Finn KT; Skinner M; Seldin DC; Ruberg FL
    Amyloid; 2011 Jun; 18 Suppl 1():130-1. PubMed ID: 21838460
    [No Abstract]   [Full Text] [Related]  

  • 27. Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis.
    Hayes-Lattin BM; Curtin PT; Fleming WH; Leis JF; Stepan DE; Schubach S; Maziarz RT
    Bone Marrow Transplant; 2002 Sep; 30(5):279-85. PubMed ID: 12209349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal IgM-related AL amyloidosis.
    Milani P; Merlini G
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):241-248. PubMed ID: 27825470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement of mucocutaneous involvement of immunoglobulin light chain amyloidosis after chemotherapy and hematopoietic stem cell transplantation for multiple myeloma.
    Hosokawa R; Ohyama M; Murakami K; Abe D; Yokoyama K; Okamoto S; Amagai M
    J Dermatol; 2013 Sep; 40(9):768-9. PubMed ID: 23855796
    [No Abstract]   [Full Text] [Related]  

  • 30. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features.
    Sidana S; Larson DP; Greipp PT; He R; McPhail ED; Dispenzieri A; Murray DL; Dasari S; Ansell SM; Muchtar E; Gonsalves WI; Kourelis TV; Ramirez-Alvarado M; Kapoor P; Rajkumar SV; Lacy MQ; Buadi FK; Leung N; Kyle RA; Kumar SK; King RL; Gertz MA
    Leukemia; 2020 May; 34(5):1373-1382. PubMed ID: 31780812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic immunoglobulin light-chain amyloidosis (AL) in Mexico: a single institution, 30-year experience.
    Hernández-Reyes J; Galo-Hooker E; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Rev Invest Clin; 2012; 64(6 Pt 2):604-8. PubMed ID: 23593777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement.
    Dispenzieri A; Buadi F; Kumar SK; Reeder CB; Sher T; Lacy MQ; Kyle RA; Mikhael JR; Roy V; Leung N; Grogan M; Kapoor P; Lust JA; Dingli D; Go RS; Hwa YL; Hayman SR; Fonseca R; Ailawadhi S; Bergsagel PL; Chanan-Khan A; Rajkumar SV; Russell SJ; Stewart K; Zeldenrust SR; Gertz MA
    Mayo Clin Proc; 2015 Aug; 90(8):1054-81. PubMed ID: 26250727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can autologous bone marrow transplantation improve systolic function in patients with multiple myeloma related cardiac amyloidosis?
    Raina S; Pant S; Vallurupalli S; Jambhekar K; Pandey T; Grazziutti M; Barlogie B; Dai Y; Deshmukh A; Mehta JL
    Int J Cardiol; 2014 Mar; 172(1):265-6. PubMed ID: 24456883
    [No Abstract]   [Full Text] [Related]  

  • 36. AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity.
    Palladini G; Russo P; Bosoni T; Sarais G; Lavatelli F; Foli A; Bragotti LZ; Perfetti V; Obici L; Bergesio F; Albertini R; Moratti R; Merlini G
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):80-3. PubMed ID: 19362981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.
    Lacy MQ; Dispenzieri A; Hayman SR; Kumar S; Kyle RA; Rajkumar SV; Edwards BS; Rodeheffer RJ; Frantz RP; Kushwaha SS; Clavell AL; Dearani JA; Sundt TM; Daly RC; McGregor CG; Gastineau DA; Litzow MR; Gertz MA
    J Heart Lung Transplant; 2008 Aug; 27(8):823-9. PubMed ID: 18656793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
    Cordes S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Kumar SK; Hogan WJ; Gertz MA
    Cancer; 2012 Dec; 118(24):6105-9. PubMed ID: 22707405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.
    Sanchorawala V; Seldin DC
    Amyloid; 2007 Dec; 14(4):261-9. PubMed ID: 17968685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.